HGS Lymphostat-B Is One Of Seven Agents Selected For CDER Continuous Marketing Pilot 2

Participation in the Pilot 2 continuous marketing application program is limited to one fast-track product per reviewing division. Human Genome Sciences’ belimumab has entered a year-long Phase II study in 350 patients with systemic lupus erythematosus.